Immunology
🇺🇸 FDA Page 3FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
Showing 25–36 of 50 articles
FDA Grants Priority Review for IMAAVY (Nipocalimab-aahu) as First Potential Treatment for Warm Autoimmune Hemolytic Anemia
ACRP 2026: Patient-Centric Trials & Workforce Expansion
ACRP 2026: Immunology Updates and Clinical Trial Insights
ACRP 2026: Immunology Updates - Day 1 Key Takeaways
ACRP 2026: Immunology Clinical Research Highlights - Day 1
ACRP 2026: Immunology Updates and Clinical Research Trends
ACRP 2026: Immunology Updates and Clinical Research Trends
ACRP 2026: Immunology Updates & Parexel Hiring Event
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
OSE Immunotherapeutics' Tedopi Ovarian Cancer Trial Results Selected for ASCO 2026 Presentation
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
FDA Issues Complete Response Letter for Atara Biotherapeutics' EBVALLO Cancer Treatment, Triggering Securities Lawsuit